Monitoring and reversal strategies for new oral anticoagulants.

@article{Daelen2015MonitoringAR,
  title={Monitoring and reversal strategies for new oral anticoagulants.},
  author={Sophie Vanden Daelen and Marijke Peetermans and Thomas Vanassche and Peter B. Verhamme and Erik Vandermeulen},
  journal={Expert review of cardiovascular therapy},
  year={2015},
  volume={13 1},
  pages={95-103}
}
Thrombin inhibitor dabigatran and factor Xa inhibitors rivaroxaban, apixaban and edoxaban form a new class of non-vitamin K antagonist oral anticoagulants and have been extensively studied in patients with venous thromboembolism and atrial fibrillation. They offer anticoagulation that is as effective and at least as safe compared to warfarin without the need for routine laboratory monitoring; however, no reversal strategies are currently validated in case of a non-vitamin K antagonist oral… CONTINUE READING
13 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

Similar Papers

Loading similar papers…